Assessment of clinical outcomes in patients with post-traumatic stress disorder: analysis from the UK Medical Cannabis Registry.

Manaswini PillaiSimon ErridgeLara BapirMartha NicholasNishaanth DalavayeCarl HolveyRoss CoomberDaniela BarrosUrmila BhoskarGracia MwimbaKavita PraveenChris SymeonSimmi Sachdeva-MohanJames J RuckerMikael Hans Sodergren

Published in: Expert review of neurotherapeutics (2022)

Associated improvements in HRQoL were observed in patients who initiated CBMP therapy. Adverse events analysis suggests acceptability and safety up to 6 months. This study may inform randomized placebo-controlled trials, required to confirm causality and determine optimal dosing.

Keyphrases

placebo controlled
double blind
healthcare
open label
clinical trial
phase iii
stem cells
emergency department
depressive symptoms
mesenchymal stem cells
drug induced
locally advanced